Product code PCI— Microbiology

BD Enteric Bacterial Panel for BD COR System, BD Enteric Bacterial Panel plus for BD COR System, and Enteric Bacterial Panel Diluent for BD COR System

Classification name
Gastrointestinal Bacterial Panel Multiplex Nucleic Acid-Based Assay System
Device class
Class 2
Regulation
21 CFR 866.3990
Advisory panel
Microbiology
Total cleared
5
First cleared
Most recent

FDA classification definition

“A gastrointestinal bacterial panel multiplex nucleic acid assay is a qualitative in vitro diagnostic device intended to simultaneously detect and identify multiple gastrointestinal bacterial nucleic acids extracted from human stool specimens. The detection and identification of a specific gastrointestinal bacterial nucleic acid from individuals exhibiting signs and/or symptoms of gastrointestinal infection aids in the diagnosis of gastrointestinal infection when used in conjunction with clinical evaluation and other laboratory findings.”

— U.S. Food and Drug Administration, device classification record for product code PCI under 21 CFR 866.3990, via openFDA

Market context for product code PCI

FDA has cleared 5 devices under product code PCI between 2014 and 2025, filed by 3 applicant companies. No FDA device recalls reference this product code. Class II devices are moderate-risk and subject to general and special controls; most reach market through 510(k) clearance by demonstrating substantial equivalence to a predicate device.

Clearances per year

Top applicants under product code PCI

Recent clearances under product code PCI

Data sourced from openFDA. This site is unofficial and independent of the FDA.